4.6 Article

Glycosaminoglycan Analysis of FFPE Tissues from Prostate Cancer and Benign Prostate Hyperplasia Patients Reveals Altered Regulatory Functions and Independent Markers for Survival

Journal

CANCERS
Volume 14, Issue 19, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14194867

Keywords

glycosaminoglycan; heparan sulfate; chondroitin sulfate; prostate cancer; benign prostate hyperplasia; HPLC; mass spectrometry; proteoglycan; glycomics

Categories

Funding

  1. National Research, Development, and Innovation Fund of Hungary [2018-1.2.1-NKP-2018-00005, 2018-1.2.1-NKP, PD_16, FK_19]
  2. [PD 121187]
  3. [FK 131603]

Ask authors/readers for more resources

This study investigated the differences in glycosaminoglycan disaccharides between patients with prostate cancer and benign prostate hyperplasia. The study found that the sulfation of chondroitin sulfate chains and the levels of doubly and triply sulfated heparan sulfate disaccharides were significantly different between the two groups. These disaccharides were found to be independent biomarkers for survival.
Simple Summary Prostate cancer is one of the most frequent cancer types among men. A better understanding of the involved molecular mechanisms is still necessary for the improvement of therapeutic decision making. Glycosaminoglycan disaccharides were investigated on biopsies taken from patients with prostate cancer and benign prostate hyperplasia. We found that the quantity and sulfation of chondroitin sulfate chains significantly differed between benign prostate hyperplasia and the distinct risk groups of prostate cancer. Doubly and triply sulfated heparan sulfate disaccharides were identified as the independent biomarkers for survival. Prostate cancer is one of the most frequent cancer types among men. Several biomarkers and risk assessment methods are already available; however, enhancing their selectivity and sensitivity is still necessary. For improving therapeutic decisions, both basic and clinical research studies are still ongoing for a better understanding of the underlying molecular mechanisms. The enzymatic digests of heparan sulfate (HS) and chondroitin sulfate (CS) chains were investigated in tissue samples taken from patients with prostate cancer (PCa) and benign prostate hyperplasia (BPH) with the HPLC-MS methodology. None of the HS species analyzed showed correlating alterations with currently used markers such as clinical stage, Gleason score, or prostate-specific antigen (PSA) level. The total quantity and sulfation motifs of CS were both significantly different among BPH and different risk groups of PCa. Furthermore, the cancer-specific survival of patients can be predicted based on the levels of non-sulfated and doubly sulfated CS disaccharides as well as the total HS content and the doubly and triply sulfated HS disaccharide ratios. These disaccharide ratios proved to be independent markers from clinical parameters. Further investigations of glycosaminoglycan motifs were proposed for the validation of the results on independent patient cohorts as well.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available